A 197574
Alternative Names: A-197574Latest Information Update: 23 Jan 2013
At a glance
- Originator Abbott Laboratories
- Class Antineoplastics
- Mechanism of Action Farnesyltranstransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 31 Dec 2012 Discontinued - Preclinical for Solid tumours in USA (unspecified route) before 2012
- 28 May 1999 Preclinical development for Solid tumours in USA (Unknown route)